Journal article
Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
Abstract
OBJECTIVE: To present current strategies for the treatment of hemophilia and von Willebrand's disease.
OPTIONS: Prophylactic and corrective therapy with hemostatic and adjunctive agents: DDAVP (1-desamino-8-D-arginine vasopressin [desmopressin acetate]), recombinant coagulation products (human Factor VIII and human Factor VIIa) or virally inactivated plasma-derived products (high- or ultra-high-purity human Factor VIII or human Factor VIII …
Journal
Canadian Medical Association Journal, Vol. 153, No. 2, pp. 147–157
Publication Date
July 15, 1995
ISSN
0820-3946